AR121692A1 - Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas - Google Patents

Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas

Info

Publication number
AR121692A1
AR121692A1 ARP210100788A ARP210100788A AR121692A1 AR 121692 A1 AR121692 A1 AR 121692A1 AR P210100788 A ARP210100788 A AR P210100788A AR P210100788 A ARP210100788 A AR P210100788A AR 121692 A1 AR121692 A1 AR 121692A1
Authority
AR
Argentina
Prior art keywords
binding
antigen
molecule
multispecific antigen
gpc3
Prior art date
Application number
ARP210100788A
Other languages
English (en)
Inventor
Sotaro Naoi
Shu Feng
Siok Wan Gan
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR121692A1 publication Critical patent/AR121692A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una molécula de unión a antígeno que comprende una primera porción de unión a antígeno que es capaz de unirse a CD3 y CD137 (4-1BB), pero no se une a CD3 y CD137 al mismo tiempo (es decir, se une doblemente a CD3 y CD137 pero no simultáneamente); y se proporciona una segunda porción de unión a antígeno capaz de unirse a una molécula expresada específicamente en un tejido canceroso, específicamente Glypican-3 (GPC3). Debido a la unión dual a CD3 y CD137 pero no simultáneamente y con cinética de unión ajustada, y la unión a GPC3, la molécula multiespecífica de unión al antígeno expresa una fuerte actividad citotóxica para las células cancerosas con efectos adversos reducidos. Además, mediante la adaptación de tecnologías de ingeniería de anticuerpos y un diseño de formato molecular (incluidas mutaciones cargadas en la región marco y/o región constante, intercambio VH / VL y selección de la región Fc), la molécula multiespecífica de unión al antígeno con estabilidad, capacidad de fabricación / capacidad de producción favorables y se proporciona homogeneidad estructural.
ARP210100788A 2020-03-31 2021-03-30 Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas AR121692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020062357 2020-03-31

Publications (1)

Publication Number Publication Date
AR121692A1 true AR121692A1 (es) 2022-06-29

Family

ID=77928944

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100788A AR121692A1 (es) 2020-03-31 2021-03-30 Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas

Country Status (9)

Country Link
US (1) US20230147840A1 (es)
EP (1) EP4126958A1 (es)
JP (1) JP2021175391A (es)
KR (1) KR20220161156A (es)
CN (1) CN115315447A (es)
AR (1) AR121692A1 (es)
SG (1) SG11202105566TA (es)
TW (1) TW202204410A (es)
WO (1) WO2021200896A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI712421B (zh) 2013-11-11 2020-12-11 日商中外製藥股份有限公司 含改變的抗體可變區之抗原結合分子
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
PL3130606T3 (pl) 2014-04-07 2022-02-07 Chugai Seiyaku Kabushiki Kaisha Przeciwciała dwuswoiste aktywujące układ odpornościowy
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11952422B2 (en) * 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
SG11202102882YA (en) * 2018-09-28 2021-04-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule comprising altered antibody variable region
AU2019347412A1 (en) * 2018-09-28 2021-05-27 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules capable of binding CD3 and CD137 but not simultaneously

Also Published As

Publication number Publication date
EP4126958A1 (en) 2023-02-08
TW202204410A (zh) 2022-02-01
CN115315447A (zh) 2022-11-08
SG11202105566TA (en) 2021-11-29
WO2021200896A1 (en) 2021-10-07
JP2021175391A (ja) 2021-11-04
US20230147840A1 (en) 2023-05-11
KR20220161156A (ko) 2022-12-06

Similar Documents

Publication Publication Date Title
AR121692A1 (es) Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas
Kugeratski et al. Quantitative proteomics identifies the core proteome of exosomes with syntenin-1 as the highest abundant protein and a putative universal biomarker
Mulder et al. Visualizing ribosome biogenesis: parallel assembly pathways for the 30 S subunit
Lajoie et al. Designed protein logic to target cells with precise combinations of surface antigens
Muda et al. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono-and bispecific antibodies
Hurtado et al. Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ
CO2021005528A2 (es) Moléculas de unión a antígeno capaces de unirse al cúmulo de diferenciación 3 (cd3) y al cúmulo de diferenciación 137 (cd137) pero no simultáneamente
AR069776A1 (es) Anticuerpos bivalentes biespecificos
EA200900424A1 (ru) Человеческие антитела, которые связываются с cxcr4, и их применение
Qiu et al. Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget
Chess et al. Reactive oxidant and p42/44 MAP kinase signaling is necessary for mechanical strain-induced proliferation in pulmonary epithelial cells
Heads et al. Relative stabilities of IgG1 and IgG4 Fab domains: Influence of the light–heavy interchain disulfide bond architecture
Kida et al. Cell surface-fluorescence immunosorbent assay for real-time detection of hybridomas with efficient antibody secretion at the single-cell level
Dippong et al. Hapten-specific single-cell selection of hybridoma clones by fluorescence-activated cell sorting for the generation of monoclonal antibodies
Do et al. Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras
Belaadi et al. SUN2 regulates mitotic duration in response to extracellular matrix rigidity
Shi et al. Bioanalysis in the age of new drug modalities
Ito et al. Single-chain tandem macrocyclic peptides as a scaffold for growth factor and cytokine mimetics
Yang et al. Constructing GFP-based reporter to study back splicing and translation of circular RNA
Copur et al. Novel strategies in nephrology: what to expect from the future?
Ding et al. Discovery of novel d-(+)-biotin-conjugated resorcinol dibenzyl ether-based PD-L1 inhibitors for targeted cancer immunotherapy
Wang et al. Identification of indocyanine green as a STT3B inhibitor against mushroom α-amanitin cytotoxicity
Wu et al. Molecular Snuggle and Stretch of a Tetraammonium Chain in the Construction of a Hetero-[4] pseudorotaxane with CyclopentanoQ [6] and Classical Q [7]
BR112022014333A2 (pt) Anticorpos multiespecíficos para uso no tratamento de doenças
Deng et al. Mechanism of tacrolimus-induced chronic renal fibrosis following transplantation is regulated by ox-LDL and its receptor, LOX-1

Legal Events

Date Code Title Description
FB Suspension of granting procedure